TrialThe Lancet. Oncology2020

Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Hironobu Hashimoto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.